344079-M

Flurbiprofen

A mixture of S(+) and R(-) enantiomers.

• Sinónimos: Flurbiprofen, (±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
• Fórmula empírica (notación de Hill): C₁₅H₁₃FO₂
• Número de CAS: 5104-49-4
• Peso molecular: 244.26
• Número MDL: MFCD00079303
• Código UNSPSC: 12352200

Propiedades

• Nivel de calidad: 100
• Ensayo: ≥98% (HPLC)
• Formulario: solid
• fabricante / nombre comercial: Calbiochem^®
• condiciones de almacenamiento: OK to freeze
• color: white
• solubilidad: DMSO: 50 mg/mL
• temp. de almacenamiento: 10-30°C
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
• Clave InChI: SYTBZMRGLBWNTM-UHFFFAOYSA-N

Descripción

Descripción general

A mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.

A mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice

Acciones bioquímicas o fisiológicas

Primary Target
Cyclooxygenase

Target IC₅₀: 5 nM for LPS-induced COX

Advertencia

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

Reconstitución

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.

Otras notas

Jantzen, P.T., et al. 2002. J. Neurosci.22, 2246.
Hinz, R., et al. 2001. Pharmacol. Res.18, 151.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Range, S.P., et al. 2000. Eur. Respir. J.15, 751.
van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther.16, 353.
Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther.282, 339.
Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol.75, 1088.
Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Pictogramas: GHS06
• Palabra de señalización: Danger
• Frases de peligro: H301
• Consejos de prudencia: P264 - P270 - P301 + P310 - P405 - P501
• Clasificaciones de peligro: Acute Tox. 3 Oral
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable